저분자량 헤파린 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "저분자량 헤파린" in Korean language version.

refsWebsite

Global rank Korean rank

13nih.gov

4^th place

10doi.org

2^nd place

3^rd place

5semanticscholar.org

11^th place

310^th place

1tip.org.pl

low place

1psu.edu

207^th place

220^th place

1enotes.com

3,553^rd place

2,333^rd place

1web.archive.org

1^st place

1massgeneral.org

low place

1archive.today

14^th place

15^th place

archive.today

massgeneral.org > Heparin Antifactor Xa Assay 보관됨 2009-08-08 - archive.today Page Updated: September 18, 2009

doi.org

dx.doi.org

Weitz JI (September 1997). “Low-molecular-weight heparins”. 《The New England Journal of Medicine》 337 (10): 688–698. doi:10.1056/NEJM199709043371007. PMID 9278467.
Garcia DA, Baglin TP, Weitz JI, Samama MM (February 2012). “Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines”. 《Chest》 141 (2 Suppl): e24S–e43S. doi:10.1378/chest.11-2291. PMC 3278070. PMID 22315264.
Hull RD (March 2008). “Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings”. 《Thrombosis and Haemostasis》 99 (3): 502–510. doi:10.1160/TH07-08-0500. PMID 18327398. S2CID 25247285.
Snow V, Qaseem A, Barry P, Hornbake ER, Rodnick JE, Tobolic T, 외. (February 2007). “Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians”. 《Annals of Internal Medicine》 146 (3): 204–210. doi:10.7326/0003-4819-146-3-200702060-00149. PMID 17261857.
Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA (February 2007). “Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients”. 《Annals of Internal Medicine》 146 (4): 278–288. CiteSeerX 10.1.1.694.4563. doi:10.7326/0003-4819-146-4-200702200-00007. PMID 17310052. S2CID 27605124.
Montalescot G, Ellis SG, de Belder MA, Janssens L, Katz O, Pluta W, 외. (February 2010). “Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)”. 《JACC. Cardiovascular Interventions》 3 (2): 203–212. doi:10.1016/j.jcin.2009.11.012. PMID 20170878.
Dumaine R, Borentain M, Bertel O, Bode C, Gallo R, White HD, 외. (December 2007). “Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials”. 《Archives of Internal Medicine》 167 (22): 2423–2430. doi:10.1001/archinte.167.22.2423. PMID 18071163.
Nishioka J, Goodin S (June 2007). “Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival”. 《Journal of Oncology Pharmacy Practice》 13 (2): 85–97. doi:10.1177/1078155207079169. PMID 17873108. S2CID 39517086.
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, 외. (July 2003). “Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer”. 《The New England Journal of Medicine》 349 (2): 146–153. doi:10.1056/NEJMoa025313. PMID 12853587. S2CID 19280602.
Lim W, Dentali F, Eikelboom JW, Crowther MA (May 2006). “Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency”. 《Annals of Internal Medicine》 144 (9): 673–684. doi:10.7326/0003-4819-144-9-200605020-00011. PMID 16670137. S2CID 29713358.

enotes.com

enotes.com > Encyclopedia of Nursing & Allied Health > Coagulation Tests Archived 2010년 9월 18일 - 웨이백 머신 Retrieved on April 5, 2010

massgeneral.org

www2.massgeneral.org

massgeneral.org > Heparin Antifactor Xa Assay 보관됨 2009-08-08 - archive.today Page Updated: September 18, 2009

nih.gov

ncbi.nlm.nih.gov

Weitz JI (September 1997). “Low-molecular-weight heparins”. 《The New England Journal of Medicine》 337 (10): 688–698. doi:10.1056/NEJM199709043371007. PMID 9278467.
Linhardt RJ, Gunay NS (1999). “Production and chemical processing of low molecular weight heparins”. 《Seminars in Thrombosis and Hemostasis》 25 (Suppl 3): 5–16. PMID 10549711.
Garcia DA, Baglin TP, Weitz JI, Samama MM (February 2012). “Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines”. 《Chest》 141 (2 Suppl): e24S–e43S. doi:10.1378/chest.11-2291. PMC 3278070. PMID 22315264.
Hull RD (March 2008). “Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings”. 《Thrombosis and Haemostasis》 99 (3): 502–510. doi:10.1160/TH07-08-0500. PMID 18327398. S2CID 25247285.
Snow V, Qaseem A, Barry P, Hornbake ER, Rodnick JE, Tobolic T, 외. (February 2007). “Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians”. 《Annals of Internal Medicine》 146 (3): 204–210. doi:10.7326/0003-4819-146-3-200702060-00149. PMID 17261857.
Douketis JD, Moinuddin I (April 2008). “Prophylaxis against venous thromboembolism in hospitalized medical patients: an evidence-based and practical approach”. 《Polskie Archiwum Medycyny Wewnetrznej》 118 (4): 209–215. PMID 18575420.
Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA (February 2007). “Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients”. 《Annals of Internal Medicine》 146 (4): 278–288. CiteSeerX 10.1.1.694.4563. doi:10.7326/0003-4819-146-4-200702200-00007. PMID 17310052. S2CID 27605124.
Montalescot G, Ellis SG, de Belder MA, Janssens L, Katz O, Pluta W, 외. (February 2010). “Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)”. 《JACC. Cardiovascular Interventions》 3 (2): 203–212. doi:10.1016/j.jcin.2009.11.012. PMID 20170878.
Dumaine R, Borentain M, Bertel O, Bode C, Gallo R, White HD, 외. (December 2007). “Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials”. 《Archives of Internal Medicine》 167 (22): 2423–2430. doi:10.1001/archinte.167.22.2423. PMID 18071163.
Nishioka J, Goodin S (June 2007). “Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival”. 《Journal of Oncology Pharmacy Practice》 13 (2): 85–97. doi:10.1177/1078155207079169. PMID 17873108. S2CID 39517086.
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, 외. (July 2003). “Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer”. 《The New England Journal of Medicine》 349 (2): 146–153. doi:10.1056/NEJMoa025313. PMID 12853587. S2CID 19280602.
Lim W, Dentali F, Eikelboom JW, Crowther MA (May 2006). “Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency”. 《Annals of Internal Medicine》 144 (9): 673–684. doi:10.7326/0003-4819-144-9-200605020-00011. PMID 16670137. S2CID 29713358.
Cardiovascular Disease Educational Research Trust; Cyprus Cardiovascular Disease Educational Research Trust; International Surgical Thrombosis Forum; International Union of Angiology; Union Internationale de Phlébologie (June 2006). “Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence)”. 《International Angiology》 25 (2): 101–161. PMID 16763532.

psu.edu

citeseerx.ist.psu.edu

Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA (February 2007). “Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients”. 《Annals of Internal Medicine》 146 (4): 278–288. CiteSeerX 10.1.1.694.4563. doi:10.7326/0003-4819-146-4-200702200-00007. PMID 17310052. S2CID 27605124.

semanticscholar.org

api.semanticscholar.org

Hull RD (March 2008). “Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings”. 《Thrombosis and Haemostasis》 99 (3): 502–510. doi:10.1160/TH07-08-0500. PMID 18327398. S2CID 25247285.
Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA (February 2007). “Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients”. 《Annals of Internal Medicine》 146 (4): 278–288. CiteSeerX 10.1.1.694.4563. doi:10.7326/0003-4819-146-4-200702200-00007. PMID 17310052. S2CID 27605124.
Nishioka J, Goodin S (June 2007). “Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival”. 《Journal of Oncology Pharmacy Practice》 13 (2): 85–97. doi:10.1177/1078155207079169. PMID 17873108. S2CID 39517086.
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, 외. (July 2003). “Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer”. 《The New England Journal of Medicine》 349 (2): 146–153. doi:10.1056/NEJMoa025313. PMID 12853587. S2CID 19280602.
Lim W, Dentali F, Eikelboom JW, Crowther MA (May 2006). “Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency”. 《Annals of Internal Medicine》 144 (9): 673–684. doi:10.7326/0003-4819-144-9-200605020-00011. PMID 16670137. S2CID 29713358.

tip.org.pl

Douketis JD, Moinuddin I (April 2008). “Prophylaxis against venous thromboembolism in hospitalized medical patients: an evidence-based and practical approach”. 《Polskie Archiwum Medycyny Wewnetrznej》 118 (4): 209–215. PMID 18575420.

web.archive.org

enotes.com > Encyclopedia of Nursing & Allied Health > Coagulation Tests Archived 2010년 9월 18일 - 웨이백 머신 Retrieved on April 5, 2010